Drugs / Human Papillomavirus Vaccine
Human Papillomavirus Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00829608 | Jan → Dec 2009 | recurrent respiratory papillomatosis | University of Missouri-Columbia | Withdrawn | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01928225 | Sep 2014 → Nov 2017 | cervical intraepithelial neoplasia grade 2/3 | University of Witwatersrand, South Africa | Completed | Missed primary |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-24 | Serum Institute of India Pvt. Ltd. | Serum Institute Of India launches the first made-in-India qHPV vaccine 'CERVAVAC' seruminstitute.com ↗ |
| 2022-09-01 | Serum Institute of India Pvt. Ltd. | Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’ seruminstitute.com ↗ |
| 2014-02-20 | Merck Sharp & Dohme LLC | FDA Accepts for Review Merck’s Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine merck.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Papillomavirus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00829608 ↗ |
| Known as | Gardasil, HPV vaccine | “Gardasil, HPV vaccine” NCT00829608 ↗ |
| Known as | qHPV vaccine | “qHPV vaccine” NCT01928225 ↗ |
| Modality | Vaccine | “quadrivalent HPV vaccine” NCT00829608 ↗ |
| Route | Intramuscular | “given intramuscularly” NCT00829608 ↗ |